CL
ADAP

CSS LLC’s Adaptimmune Therapeutics ADAP Stock Holding History

CSS LLC’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,702
Closed -$6.05K – 959
2025
Q1 		$6.05K Hold
30,702
– – ﹤0.01% 894
2024
Q4 		$16.5K Hold
30,702
– – ﹤0.01% 930
2024
Q3 		$29.2K Hold
30,702
– – ﹤0.01% 766
2024
Q2 		$29.9K Hold
30,702
– – ﹤0.01% 811
2024
Q1 		$48.5K Hold
30,702
– – ﹤0.01% 738
2023
Q4 		$24.3K Sell
30,702
-60,000
-66% -$33.8K ﹤0.01% 745
2023
Q3 		$70.7K Hold
90,702
– – ﹤0.01% 716
2023
Q2 		$83.9K Buy
+90,702
New +$108K 0.01% 751

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CSS LLC's ADAP Position: Q2 2025 in Review

CSS LLC sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 30,702 shares — an estimated $6.05K sold.

CSS LLC first reported a position in ADAP in Q2 2023 and held it in 8 quarters. The position peaked at $83.9K in Q2 2023. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • CSS LLC reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CSS LLC sold 30,702 Adaptimmune Therapeutics shares in Q2 2025, an estimated $6.05K.
  • CSS LLC first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 8 quarters.
  • CSS LLC's Adaptimmune Therapeutics position peaked at $83.9K in Q2 2023.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on CSS LLC's 13F filing for Q2 2025, filed 14 Aug 2025.